Positive phase III METEOR results for Cometriq (cabozantinib) in renal cell carcinoma- Exelisis
Exelixis has announced positive overall survival (OS) results from METEOR, the phase III pivotal trial comparing Cometriq (cabozantinib) to everolimus in 658 patients with advanced renal cell carcinoma (RCC) who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor (TKI). In a second interim analysis for OS, a secondary endpoint of the trial, the results showed a highly statistically significant and clinically meaningful increase in OS for patients randomized to cabozantinib as compared to everolimus. Ongoing study monitoring did not identify any new safety signals. Exelixis intends to present these data at a medical meeting later this year.
Comment: the company has just submitted a marketing application to the EMA for renal cell carcinoma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins